The Chinese version of the Personal and Social Performance Scale (PSP): Validity and reliability

Psychiatry Research

Volumn 185, Issue 1-2, 2011, Pages 275-279

  Tianmei, Si ^a   Liang, Shu ^a   Yun'ai, Su ^a   Chenghua, Tian ^a   Jun, Yan ^a   Jia, Cheng ^a   Xueni, Li ^a   Qi, Liu ^a   Yantao, Ma ^a   Weihua, Zhang ^a   Hongyan, Zhang ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

Author keywords

Chinese Version Personal and Social Performance Scale (PSP); Reliability; Schizophrenia; Validity

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CONSTRUCT VALIDITY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING SCALE; HUMAN; HUMAN RELATION; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; PERSONAL AND SOCIAL PERFORMANCE SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL INTERACTION; TEST RETEST RELIABILITY;

ADULT; CHINA; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PERSONALITY; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOCIAL BEHAVIOR; TRANSLATING;

EID: 78650210456     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.05.001     Document Type: Article

References (33)

1. Apiquian R., Elena Ulloa R., Herrera-Estrella M., Moreno-Gomez A., Erosa S., Contreras V., Nicolini H. Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophrenia Research 2009, 112:181-186.
2. Bell M.D., Bryson G. Work rehabilitation in schizophrenia: does cognitive impairment limit improvement?. Schizophrenia Bulletin 2001, 27:269-279.
3. Bodlund O., Kullgren G., Ekselius L., Lindstrom E., von Knorring L. Axis V-Global Assessment of Functioning Scale. Evaluation of a self-report version. Acta Psychiatrica Scandinavica 1994, 90:342-347.
4. Bryson G., Bell M.D. Initial and final work performance in schizophrenia: cognitive and symptom predictors. Journal of Nervous and Mental Disease 2003, 191:87-92.
5. Burns T., Patrick D. Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica 2007, 116:403-418.
6. Cohen J. The statistical power of abnormal-social psychological research: a review. Journal of Abnormal Social Psychology 1962, 65:145-153.
7. Csernansky J.G., Schuchart E.K. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002, 16:473-484.
8. Davidson M., Emsley R., Kramer M., Ford L., Pan G., Lim P., Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research 2007, 93:117-130.
9. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976, 33:766-771.
10. Freedman R. Schizophrenia. New England Journal of Medicine 2003, 349:1738-1749.
11. Gagnon D.D., Nasrallah H., Morosini P.L. Reliability, validity and sensitivity to change of the Personal and Social Performance Scale in patients with stable schizophrenia. The International Journal of Neuropsychopharmacology 2006, 9(Suppl 1):S288. (Abstract).
12. Goldman H.H., Skodol A.E., Lave T.R. Revising axis V for DSM-IV: a review of measures of social functioning. American Journal of Psychiatry 1992, 149:1148-1156.
13. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophrenia Bulletin 2000, 26:119-136.
14. Hall R.C. Global assessment of functioning. A modified scale. Psychosomatics 1995, 36:267-275.
15. Hwu H.G., Tan H., Chen C.C., Yeh L.L. Negative symptoms at discharge and outcome in schizophrenia. British Journal of Psychiatry 1995, 166:61-67.
16. Jablensky A. Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. Australian and New Zealand Journal of Psychiatry 2000, 34:S26-S34. Suppl.
17. Javitt D.C., Spencer K.M., Thaker G.K., Winterer G., Hajos M. Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews Drug Discovery 2008, 7:68-83.
18. Juckel G., Morosini P.L. The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Current Opinion in Psychiatry 2008, 21:630-639.
19. Juckel G., Schaub D., Fuchs N., Naumann U., Uhl I., Witthaus H., Hargarter L., Bierhoff H.W., Brune M. Validation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophrenia. Schizophrenia Research 2008, 104:287-293.
20. Kane J., Canas F., Kramer M., Ford L., Gassmann-Mayer C., Lim P., Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophrenia Research 2007, 90:147-161.
21. Kasckow J.W., Twamley E., Mulchahey J.J., Carroll B., Sabai M., Strakowski S.M., Patterson T., Jeste D.V. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Research 2001, 103:69-78.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
23. Kramer M., Simpson G., Maciulis V., Kushner S., Vijapurkar U., Lim P., Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2007, 27:6-14.
24. Marder S.R., Kramer M., Ford L., Eerdekens E., Lim P., Eerdekens M., Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry 2007, 62:1363-1370.
25. McGurk S.R., Meltzer H.Y. The role of cognition in vocational functioning in schizophrenia. Schizophrenia Research 2000, 45:175-184.
26. McGurk S.R., Mueser K.T., Harvey P.D., LaPuglia R., Marder J. Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatric Services 2003, 54:1129-1135.
27. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 2000, 101:323-329.
28. Muller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 2004, 37(Suppl 2):S141-S147.
29. Patrick D., Morosini P.L., Rothman M. Reliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with acute schizophrenia. The International Journal of Neuropsychopharmacology 2006, 9(Suppl 1):S287-S288. (Abstract).
30. Rund B.R., Borg N.E. Cognitive deficits and cognitive training in schizophrenic patients: a review. Acta Psychiatrica Scandinavica 1999, 100:85-95.
31. Srisurapanont M., Arunpongpaisal S., Chuntaruchikapong S., Silpakit C., Khuangsirikul V., Karnjanathanalers N., Samanwongthai U. Cross-cultural validation and inter-rater reliability of the Personal and Social Performance scale, Thai version. Journal of the Medical Association of Thailand 2008, 91:1603-1608.
32. Startup M., Jackson M.C., Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). British Journal of Clinical Psychology 2002, 41:417-422.
33. Swanson J.W., Holzer C.E., Ganju V.K., Jono R.T. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hospital and Community Psychiatry 1990, 41:761-770.